Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06180499
Other study ID # P120103
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2024
Est. completion date September 2029

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact sébastien maury, PhD
Phone 01.49.81.20.57
Email sebastien.maury@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Since the discovery that Treg suppress anti-tumor immune responses, inhibiting their function has become a major challenge for the development of efficient immunotherapy for cancer. In humans, we previously reported the positive results of a first clinical trial using Treg depletion for anti-tumor response amplification in the field of allogeneic hematopoietic stem cell transplantation (HSCT). The present project aims at developing this anti-tumor immunotherapeutic strategy in the same setting, i.e. donor lymphocyte infusion (DLI) for relapsing hematological malignancies after HSCT, using a new selection marker: CD127. The choice of this new strategy is supported by our results of a retrospective clinical study and pre-clinical data. Using human cells, this studies demonstrated, in vitro and in vivo in animal murine models, that Treg depletion through CD127 positive selection is much more efficient to improve allogeneic immune responses of donor T-cells as compared to the previous strategy using the CD25 marker.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 27
Est. completion date September 2029
Est. primary completion date November 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patient (older than 18 years old without upper limit of age) diagnosed with leukemia, myelodysplasia, myeloproliferative disorder or lymphoproliferative disorder (CLL, myeloma, lymphoma) - Previous allogeneic HSCT from a matched sibling, haplo-identical or unrelated donor (any type of conditioning regimen) - Haematological relapse (molecular, cytogenetic or cytological) after HSCT - Patient refractory (no or partial response) to one or several previous standard unmanipulated DLI - Availability of cryopreserved lymphapheresis - No loss of chance by using of DLI rather than more incisive anti-tumor agents according to investigator appreciation - Written informed consent before any intervention necessary for the trial - Affiliation to a social security regime - Negative pregnancy test for women of childbearing age participating in the study - Effective contraceptive methods for men / women in line with the current CTFG recommendations version 1.1 Exclusion Criteria: - Acute grade = II or moderate/severe chronic GVHD at the time of inclusion - Patient receiving immunosuppressive treatment for GVHD or any other reason - Creatinine clearance< 50 ml/min - Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 5.0 x upper limit of normal (ULN) - Serum total bilirubin > 50µM (expect for unconjugated hyperbilirubinemia due to Gilbert's disease) - Performance status ECOG>1 - Severe infection according to CTCAE grading (grade>2) - Pregnant or lactating women - Patient under tutorship, curatorship or legal protection - Ongoing participation in another interventional research protocol within the same field of immune modulation (through cell therapy or not) - State medical aid

Study Design


Intervention

Drug:
T-reg depleted DLI
Treg depleted Donor Lymphocytes Infusion

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary cumulative incidence of GVHD in its acute grade = II and/or severe chronic form (according Glucksberg-Thomas and NIH scales, respectively), and uncontrolled after a 14-day immunosuppressive course including steroids. Composite criteria. In this evaluation, death from non-GVHD cause will be taken as a competitive event occurring within the 2 months following d-DLI infusion
Secondary Incidence of acute and/or chronic GVHD, with corresponding grades according to NIH and Glucksberg-Thomas scales at 2 and 12 month
Secondary Date of putative relapse/progression for estimation of cumulative incidence (taking into account the competitive risk of death not related to relapse) at 2 and 12 month
Secondary Date of putative relapse/progression for estimation disease-free survival at 2 and 12 month
Secondary Number, causes and date of deaths at 2 and 12 month
See also
  Status Clinical Trial Phase
Terminated NCT03248479 - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Phase 1
Recruiting NCT05454241 - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies Phase 2
Recruiting NCT06041815 - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting NCT05005442 - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Phase 2
Recruiting NCT02300571 - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant N/A
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Completed NCT00379587 - Rituximab for Prevention of Chronic GVHD Phase 1/Phase 2
Completed NCT01162096 - Reduced Intensity Haploidentical Transplant for Hematological Malignancies Phase 1/Phase 2
Terminated NCT00506948 - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) Phase 2
Active, not recruiting NCT04557098 - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 2
Recruiting NCT04283097 - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Phase 1
Completed NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. Phase 2
Completed NCT01725555 - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors Phase 1
Completed NCT00438178 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Phase 1
Completed NCT03711604 - Compassionate Use Study of Tenalisib (RP6530) Phase 1/Phase 2
Withdrawn NCT01168882 - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies Phase 1
Completed NCT01246206 - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Phase 2
Completed NCT01172132 - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" N/A
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT00163644 - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT N/A